$HROW

HARROW, INC. (HROW): Submission of Matters to a Vote of Security Holders

HARROW, INC. (HROW) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001360214 0001360214 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jun 22, 2026, 11:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$HROW
Neutral
high confidence
Mentioned
$HROW
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HROWNeutralLow
01

Why it matters

The disclosure is primarily procedural: directors were elected, executive compensation was approved on an advisory basis, and Deloitte & Touche LLP was ratified as independent auditor for FY ending Dec. 31, 2026.

02

Market read

No new guidance, deal, or regulatory action—only confirmation of shareholder voting outcomes.

03

What to watch

Voting tallies (For/Withheld/Broker Non-Vote) are not tied to any disclosed strategic change, so they are unlikely to drive trading beyond governance-focused sentiment.

Relevance 6/10Novelty 2/10Timing: filed June 22, 2026 for June 18 annual meeting vote results

Background

This is an SEC Form 8-K (Item 5.07) reporting the results of Harrow’s 2026 Annual Meeting of Stockholders held June 18, 2026.

Company-level read

Ticker impact

$HROWNeutralHigh confidence
Context

Harrow filed an 8-K confirming all four director nominees were elected and other proposals approved at its June 18, 2026 annual meeting.

Expected impact

Limited near-term impact; any reaction is likely muted unless investors were specifically focused on governance outcomes.

Evidence & confidence

The filing reports voting results (board election, advisory executive comp, auditor ratification) without introducing new operating or financial information.

Market effects

None; governance vote outcomes do not change sector fundamentals.

None.

None.

Counterpoint

If investors were concerned about board composition or auditor continuity, the confirmed approvals could reduce uncertainty, but the filing still lacks new fundamentals.

Key entities

  • Harrow, Inc.

    Nasdaq-listed company whose annual meeting voting results are reported in the 8-K.

  • Deloitte & Touche LLP

    Independent registered public accounting firm ratified by stockholders for fiscal year ending Dec. 31, 2026.

Related articles

$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

$HROWMed

HARROW, INC. (HROW): Results of Operations and Financial Condition

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28 th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand into revenue and profits

$HROWMed

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow (Nasdaq: HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, for wet AMD, RVO macular edema, and mCNV. The launch follows Harrow’s exclusive U.S. commercialization agreement with Samsung Bioepis. Harrow also noted exclusive U.S. rights to OPUVIZ (aflibercept-yszy).

$MSTRMedAI 8/10

Strategy Sells 1,690 Bitcoin as USD Reserve Hits $4.65 Billion

Strategy (MSTR) sold 1,690 BTC for $108.6 million in the week ending Aug. 9, per an SEC Form 8-K. BTC sold averaged $64,262 versus an average cost basis of $75,385. Afterward it held 840,447 BTC. Proceeds funded a $108.6 million STRC preferred buyback and Strategy also raised $653.1 million net via an MSTR ATM offering.

$TLSMed

Telstra FY profit rises slightly, announces $706 mln buyback

Telstra Group reported FY profit attributable of A$2.24 billion, up 3.2% year over year, citing growth in mobile operations and higher customer spending. Mobile revenue rose 3.2% to A$11.37 billion. Telstra announced an A$1 billion share buyback and forecast 2027 EBIT after leases of A$8.5–A$8.8 billion, plus cash EBIT of A$4.75–A$4.95 billion. Final dividend was 10.5 Australian cents.